Sunesis Pharmaceuticals Inc (SNSS)
NASDAQ
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -84.275 | -91.424 | -107.193 | -88.768 | -71.453 | -174.147 | -48.104 | -66.881 |
Return on Equity (%) | -157.065 | -166.595 | -208.443 | -147.958 | -91.028 | -200.794 | -63.286 | -128.574 |
Return on Invested Capital (%) | -122.515 | -131.649 | -213.867 | -148.686 | -95.82 | -197.198 | -55.917 | -100.179 |
Operating Margin (%) | -1431.467 | -5091.48 | -10743.038 | -1100.627 | -17756.667 | N/A | N/A | N/A |
Net Profit Margin (%) | -1499.33 | -5300.149 | -11229.958 | -1125.422 | -18008.333 | N/A | N/A | N/A |
Book Value Per Share | 1.005 | 0.628 | 0.107 | 0.142 | 0.795 | 2.375 | 1.451 | 0.333 |
Earnings Per Share | -1.817 | -1.034 | -0.71 | -0.209 | -1.193 | -3.066 | -1.283 | -1.322 |
Cash Per Share | 0.385 | 0.787 | 0.365 | 0.115 | 1.127 | 2.766 | 0.959 | 0.319 |
Working Capital Per Share | 1.543 | 0.591 | 0.103 | 0.242 | 1.04 | 2.569 | 2.183 | 0.429 |
Operating Profit Per Share | 0.121 | 0.02 | 0.006 | 0.019 | 0.007 | 0.361 | N/A | N/A |
EBIT Per Share | -1.817 | -1.034 | -0.71 | -0.209 | -1.193 | -3.066 | -1.283 | -1.322 |
EBITDA Per Share | -1.817 | -1.034 | -0.71 | -0.209 | -1.193 | -3.066 | -1.283 | -1.322 |
Free Cash Flow Per Share | -1.818 | -1.034 | -0.71 | -0.209 | -1.193 | -2.957 | -1.287 | -1.331 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 20,93M | 34,29M | 37,47M | 111,39M | 18,11M | 37,43M | 38,35M | N/A |
Fin d'année 31 Décembre 2023 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | 38,35M | N/A | N/A | N/A | N/A | N/A | 39,42M | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 205,49M |
Ratio cours/bénéfice | -0,12 |
Ratio prix/ventes | 0 |
Ratio prix/liquidités | 0,5 |
Ratio prix/valeur comptable | 0,34 |
Rendement de dividende | - |
Actions en circulation | 38,63M |
Volume moyen (1 semaine) | 0 |
Volume moyen (1 mois) | 0 |
Variation sur 52 semaines | - |
Plus haut sur 52 semaines | - |
Plus bas sur 52 semaines | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales